GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Structure Therapeutics
Shares of Structure Therapeutics, a biotech developing oral obesity drugs, reflect the enormous excitement surrounding the market. The price chart is a bet that its pill will compete with injectable blockbusters from Novo Nordisk and Eli Lilly.
Share prices of companies in the market segment - Pharma metabolism
Structure Therapeutics is a biotech company developing oral medications for the treatment of obesity. This is its only segment. We classify it as part of the Pharma Metabolism sector, and the chart below reflects the dynamics of this entire "hot" biotech field.
Broad Market Index - GURU.Markets
Structure Therapeutics is a biopharmaceutical company developing oral medications for the treatment of metabolic and cardiopulmonary diseases. It is a component of the GURU.Markets index. The chart below represents the market. See how this company's stock compares to the overall biotech sector.
Change in the price of a company, segment, and market as a whole per day
GPCR - Daily change in the company's share price Structure Therapeutics
The daily price change of Structure Therapeutics, a biopharmaceutical company using AI to create drugs, reflects the sector's high volatility. Change_co measures sensitivity to research news. This metric is key to analysis of the computational biology sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma metabolism
Structure Therapeutics Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with the performance of GPCR, which focuses on metabolic disease treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Structure is a biopharmaceutical company developing oral medications for the treatment of metabolic diseases. This is one of the hottest and most volatile areas in pharmaceuticals. The chart below reflects the average fluctuations in this industry, providing context for evaluating Structure shares.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Structure Therapeutics
Structure is a biotech company specializing in the treatment of metabolic diseases. Its shares move in sync with clinical trial news. This high, event-driven volatility feeds into the overall market flow.
Annual dynamics of market capitalization of the market segment - Pharma metabolism
Structure Therapeutics Inc. is a clinical-stage biotech developing oral medications for the treatment of metabolic diseases, including obesity. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its drugs in this highly competitive field.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Structure Therapeutics is one of the hottest stories in biotech, tied to the development of anti-obesity drugs. Its stock price has nothing to do with the economy, but is driven by news of clinical trials. The chart reflects investors' high hopes for the next blockbuster.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Structure Therapeutics
Structure, a biopharmaceutical company, is a speculative company. Monthly fluctuations on the chart reflect news about the progress of clinical trials of its oral drugs for obesity and diabetes, the success of which determines its ability to compete in a vast and competitive market.
Monthly dynamics of market capitalization of the market segment - Pharma metabolism
Structure Therapeutics Inc. is a biopharmaceutical company using its platform to develop new oral drugs for the treatment of metabolic and pulmonary diseases. The dynamics of its sector, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess how the potential for developing tablet alternatives to injectable drugs (for example, for the treatment of obesity) affects the company's valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Structure Therapeutics is a biotech company developing small-molecule drugs for the treatment of metabolic diseases, including obesity. It operates in one of the hottest markets. A full-market chart allows you to assess how Structure shares, as a speculative bet on a breakout, respond to overall investor risk appetite.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Structure Therapeutics
Structure Therapeutics, a clinical-stage biotech developing oral medications for the treatment of metabolic diseases (such as obesity), is experiencing high volatility. News about clinical trials and actions by competitors like Novo Nordisk are driving short-term trends.
Weekly dynamics of market capitalization of the market segment - Pharma metabolism
Structure Therapeutics, like other biotech companies specializing in metabolism, exhibits high volatility. The chart allows you to compare its performance with the sector to see how much of its movements are driven by general sentiment and how much by specific news about its drugs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Structure Therapeutics is a biotech company developing oral drugs for the treatment of metabolic diseases. Its shares exist in a world of their own, where research data dictates everything. The chart shows that GPCR performance is almost uncorrelated with the market.
Market capitalization of the company, segment and market as a whole
GPCR - Market capitalization of the company Structure Therapeutics
The Structure Therapeutics chart is a financial map of the race for an obesity pill. This biotech company's market cap reflects hopes for its oral GLP-1 drugs, which could compete with injectable blockbusters. Its volatility mirrors clinical data and expectations for one of the largest markets in pharmaceutical history.
GPCR - Share of the company's market capitalization Structure Therapeutics within the market segment - Pharma metabolism
Structure Therapeutics is a biopharmaceutical company developing novel oral drugs for the treatment of metabolic and cardiopulmonary diseases. Its market capitalization reflects the potential of its platform to create pills in a field currently dominated by injections. The chart below shows how much the market is betting on this breakthrough.
Market capitalization of the market segment - Pharma metabolism
Structure Therapeutics develops oral medications for the treatment of metabolic diseases such as diabetes and obesity. The chart below shows the market capitalization of the entire biotech sector. Its dynamics reflect the enormous investor interest in the next generation of weight loss drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
Structure Therapeutics is a biotech company using computational methods to create small-molecule drugs, including those for the treatment of obesity. Its market cap chart is a bet on a new approach to drug development, demonstrating how technology is struggling to compete in one of the hottest areas of pharmaceuticals.
Book value capitalization of the company, segment and market as a whole
GPCR - Book value capitalization of the company Structure Therapeutics
Structure Therapeutics is a biotech company, and its book value represents R&D capital. The chart below shows not its manufacturing facilities, but the financial resources allocated to developing new drugs. Its level is an indicator of the company's ability to finance lengthy and expensive clinical trials.
GPCR - Share of the company's book capitalization Structure Therapeutics within the market segment - Pharma metabolism
Structure Therapeutics develops drugs using computational chemistry. Its core capital is intellectual property. The share of physical assets will reflect its research-focused model, where its key assets are high-tech laboratories.
Market segment balance sheet capitalization - Pharma metabolism
Structure Therapeutics uses computational methods to develop drugs for metabolic diseases. Their approach reduces the need for expensive laboratory experiments in the early stages. The chart below shows how their R&D- and patent-based model is less capital-intensive than that of traditional pharmaceutical companies.
Book value of all companies included in the broad market index - GURU.Markets
Structure Therapeutics is a scientific platform for the development of oral drugs. The company's assets include advanced laboratories, structural biology equipment, and computing power. The chart shows its resources, which are focused on developing tablet-based drugs for the treatment of metabolic diseases such as diabetes.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Structure Therapeutics
Structure Therapeutics is a biotechnology company developing small-molecule drugs. Its book value is primarily cash, while its market capitalization reflects investor confidence in its scientific platform and the potential to create oral alternatives to injectable drugs for the treatment of chronic diseases.
Market to book capitalization ratio in a market segment - Pharma metabolism
Structure Therapeutics develops small-molecule drugs for the treatment of metabolic diseases. It is an early-stage biotech company. The chart shows how the market values its scientific platform and the potential of future drugs, placing a significant premium on the value of its laboratory assets.
Market to book capitalization ratio for the market as a whole
Structure Therapeutics is a biotech company developing small-molecule drugs to treat metabolic diseases. Its value is almost entirely dependent on the success of its scientific platform and clinical trials. The chart shows how investors evaluate a potential medical breakthrough, leading to a valuation that is a multiple of its book value.
Debts of the company, segment and market as a whole
GPCR - Company debts Structure Therapeutics
Structure Therapeutics, a biotech company developing small molecule drugs, uses debt to fund its research. This chart shows the capital raised to conduct preclinical and early clinical trials of its candidates. This is a long-term investment in science aimed at creating oral alternatives to injectables.
Market segment debts - Pharma metabolism
Structure Therapeutics is a biotech company developing small-molecule drugs for the treatment of metabolic diseases. At the clinical stage, companies often use debt financing to support expensive research. The chart shows how the company's financial strategy compares to industry norms for biotech companies on the path to commercialization.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Structure Therapeutics
Structure Therapeutics is a biotech company developing small-molecule drugs for the treatment of metabolic diseases. During the clinical development stage, a solid financial foundation is crucial. This chart shows whether the company is using debt financing, which could pose a significant risk on the long road to approval and commercialization.
Market segment debt to market segment book capitalization - Pharma metabolism
Structure Therapeutics is a biopharmaceutical company developing small-molecule drugs for the treatment of metabolic and cardiopulmonary diseases. This is one of the most in-demand areas in modern pharmaceuticals. The chart shows the overall debt burden in the sector, providing context for assessing the company's financial strategy in this competitive race.
Debt to book value of all companies in the market
Structure Therapeutics develops drugs in the high-demand field of metabolic diseases. This chart shows the overall market leverage, reflecting investors' risk appetite. It helps understand how easy or difficult it is for biotech companies, even in hot sectors, to raise capital during different phases of the economic cycle.
P/E of the company, segment and market as a whole
P/E - Structure Therapeutics
Structure Therapeutics uses computational methods and AI to develop new drugs for metabolic diseases. This chart, like other biotech companies, reflects future expectations. A high value indicates investor confidence that the company's technology platform can create more effective drugs faster and more cost-effectively than traditional methods.
P/E of the market segment - Pharma metabolism
Structure Therapeutics is a biotech company. This chart shows the average price-to-earnings ratio for the industry. Comparing the company's price-to-earnings ratio to this high industry average helps us understand how disruptive investors consider its computational drug discovery platform to be compared to other biotech companies in the same field.
P/E of the market as a whole
Structure Therapeutics is a biotech company developing small-molecule drugs to treat metabolic diseases such as diabetes and obesity. Its valuation is a bet on success in one of the most competitive areas of pharmaceuticals. This chart shows the market's risk appetite and allows one to understand how clinical trial news impacts the company compared to market giants.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Structure Therapeutics
Structure Therapeutics is a biotech company developing small-molecule drugs for the treatment of metabolic and pulmonary diseases. This chart reflects investor expectations for the clinical trials of its oral GLP-1 receptor agonists (Ozempic tablets). The valuation is based on the potential for breakthrough success in a large market.
%20P%2FE%20Structure%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Structure-Therapeutics&v=1772506746776 "Chart of the company's future (projected) P/E Structure Therapeutics")
Future (projected) P/E of the market segment - Pharma metabolism
Structure Therapeutics develops small-molecule drugs for the treatment of metabolic and cardiovascular diseases, including obesity. This chart compares the company's future profitability expectations with those of the biopharmaceutical sector. It reflects the level of investor confidence in its scientific approach and ability to compete in the highly profitable weight-loss drug market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-metabolism&v=1772506746779 "Future (projected) P/E graph of the market segment - Pharma metabolism")
Future (projected) P/E of the market as a whole
Structure Therapeutics is using its platform to develop orally administered small molecules for the treatment of metabolic and pulmonary diseases. For a development-stage biotech, the overall investment climate, as reflected in this chart, is crucial. Market optimism provides access to the capital needed to fund lengthy and expensive clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772506746783 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Structure Therapeutics
Structure Therapeutics is a biotech company specializing in the development of orally administered small molecules for the treatment of metabolic diseases such as type 2 diabetes and obesity. Its financial profile reflects the R&D stage, with high research expenditures. This chart illustrates the company's trajectory, with its future value dependent on the success of clinical trials.
Profit of companies in the market segment - Pharma metabolism
Structure Therapeutics is a biotech company developing small-molecule drugs for the treatment of metabolic and pulmonary diseases. This graph, which shows the sector's total revenue, highlights the potential for new treatment approaches. The company's success in developing oral alternatives to injectables could radically change markets and generate enormous profits for the entire industry.
Overall market profit
Structure Therapeutics uses cutting-edge technologies, including AI, to develop drugs for metabolic diseases. Its approach promises to speed up and reduce the cost of creating new drugs. It's an example of a company whose value is determined not by current economic conditions, but by the potential of its technology platform to address global health challenges.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Structure Therapeutics
Structure Therapeutics is a biotechnology company developing small-molecule drugs for the treatment of metabolic and pulmonary diseases. The future revenue projections presented here are speculative. They reflect analyst expectations for clinical trial results, particularly in the popular field of GLP-1 receptor agonists.
%20profit%20of%20the%20company%20Structure%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Structure-Therapeutics&v=1772506746804 "Graph of future (projected) profit of the company Structure Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma metabolism
Structure Therapeutics is a biopharmaceutical company developing small-molecule drugs for the treatment of metabolic and pulmonary diseases. This chart reflects revenue forecasts for the entire pharmaceutical segment focused on metabolism. It shows the market's financial expectations for new approaches to treating obesity and diabetes.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-metabolism&v=1772506746807 "Graph of future (predicted) profits of companies in a market segment - Pharma metabolism")
Future (predicted) profit of the market as a whole
Structure Therapeutics is a biotech company developing small-molecule drugs for the treatment of metabolic diseases. Its prospects depend on the success of clinical trials. However, the overall market backdrop, shown in this chart, influences investor risk appetite. During growth markets, funding becomes more accessible for biotech companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772506746811 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Structure Therapeutics
Structure Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of oral drugs for the treatment of metabolic diseases. For a company like this, this chart is especially important. It reflects not current sales, but rather the enormous investor expectations for its scientific platform and the potential for creating blockbuster drugs in the future.
P/S market segment - Pharma metabolism
Structure Therapeutics is a biotech company using its platform to develop novel oral drugs for the treatment of metabolic and pulmonary diseases. The company aims to replace injectables with convenient tablets. This chart shows how investors value biotech revenue, demonstrating the level of optimism regarding Structure Therapeutics' scientific platform.
P/S of the market as a whole
Structure Therapeutics is a clinical-stage biopharmaceutical company using its platform to develop novel oral drugs for the treatment of metabolic and pulmonary diseases. Its valuation is based on the potential of its molecules. This chart shows how the market as a whole values its revenue, highlighting the high expectations for biotech innovation.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Structure Therapeutics
Structure Therapeutics is a biopharmaceutical company developing small-molecule drugs for the treatment of metabolic diseases, including obesity. This chart shows the market's estimate of its potential future revenue. It reflects the high expectations for the weight-loss drug market and the confidence in the success of its oral drug candidates.
%20P%2FS%20Structure%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Structure-Therapeutics&v=1772506746829 "The graph of the company's future (projected) P/S Structure Therapeutics")
Future (projected) P/S of the market segment - Pharma metabolism
Structure Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule oral therapies for the treatment of metabolic and pulmonary diseases. This chart compares investor expectations for its future revenue with the sector. The high valuation reflects expectations for the success of its developments in high-demand areas such as obesity.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-metabolism&v=1772506746833 "Future (projected) P/S market segment graph - Pharma metabolism")
Future (projected) P/S of the market as a whole
Structure Therapeutics is a biotechnology company developing small-molecule drugs for the treatment of metabolic and pulmonary diseases. Its future depends on the success of clinical trials. This graph of investor expectations reflects their risk appetite and belief that scientific innovation in medicine will lead to the creation of new markets and revenue streams.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772506746836 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Structure Therapeutics
Structure Therapeutics is at the forefront of developing oral therapeutics for metabolic diseases. As a clinical-stage company, its revenue is generated from partnerships rather than sales. This chart reflects the receipt of upfront and milestone payments, validating the value of its scientific platform.
Sales of companies in the market segment - Pharma metabolism
Structure Therapeutics is a biotech company specializing in the development of oral medications for the treatment of metabolic and pulmonary diseases. The company utilizes a cutting-edge drug discovery platform. This chart represents the total revenue of the entire obesity and diabetes drug market, demonstrating the enormous potential that Structure is targeting.
Overall market sales
Structure Therapeutics develops small-molecule drugs for the treatment of metabolic diseases. The company's success depends on clinical trials and partnerships. Its business is not subject to economic cycles, but the overall situation shown in this chart affects the investment climate in the biotech sector and the ability to attract capital for lengthy and expensive research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Structure Therapeutics
Structure Therapeutics is a biotechnology company specializing in the development of small-molecule oral therapies for the treatment of metabolic and cardiovascular diseases. Future revenue is dependent on the success of clinical trials. This graph represents a long-term forecast based on the potential of its drugs in major categories such as obesity and diabetes.
%20sales%20of%20the%20company%20Structure%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Structure-Therapeutics&v=1772506746856 "Schedule of future (projected) sales of the company Structure Therapeutics")
Future (projected) sales of companies in the market segment - Pharma metabolism
Structure Therapeutics is a biopharmaceutical company developing small-molecule drugs for the treatment of metabolic diseases, including obesity. This chart depicts the projected revenue potential of their leading drug candidates. The data reflects analysts' assessment of the commercial prospects of their developments in a highly competitive market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-metabolism&v=1772506746860 "Schedule of future (projected) sales of companies in the market segment - Pharma metabolism")
Future (projected) sales of the market as a whole
The biotech investment climate, illustrated by this chart, determines the prospects for Structure Therapeutics. The company uses computational methods to develop drugs for metabolic diseases. Funding for such innovative approaches depends on the overall risk appetite of investors, which is growing in a stable economy.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772506746864 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Structure Therapeutics
Structure Therapeutics is a clinical-stage biotechnology company using its computational platform to develop novel drugs targeting GPCR receptors. This graph reflects a phase of active research investment. Future profitability is entirely dependent on the success of clinical trials and commercialization of oral drugs for the treatment of metabolic diseases.
Market segment marginality - Pharma metabolism
Structure Therapeutics is a biotechnology company specializing in the development of small-molecule oral drugs for the treatment of metabolic and cardiovascular diseases. Profitability depends on the success of its developments. This chart shows the average profitability in the pharmaceutical industry. It provides context for assessing the company's potential to create convenient alternatives to injectable drugs.
Market marginality as a whole
Structure Therapeutics is a biopharmaceutical company developing small-molecule drugs for the treatment of metabolic diseases. Like many research-stage biotechs, it is dependent on funding. This chart reflects the overall investment environment and risk appetite, which determine the company's ability to raise capital for costly clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company Structure Therapeutics
Structure Therapeutics is a biotech company developing small-molecule drugs for the treatment of metabolic and pulmonary diseases. This chart shows the size of the research team using cutting-edge methods to create new drugs. Growth in the chart indicates progress in research and the expansion of R&D programs aimed at larger markets.
Share of the company's employees Structure Therapeutics within the market segment - Pharma metabolism
Structure Therapeutics uses computational methods and artificial intelligence to develop new drugs for the treatment of metabolic and pulmonary diseases. This chart shows the percentage of all scientists working at the intersection of biology and IT that the company employs. This indicates its innovative approach and potential for creating next-generation drugs.
Number of employees in the market segment - Pharma metabolism
Structure Therapeutics develops small-molecule drugs for the treatment of metabolic and pulmonary diseases. This chart shows the employment dynamics in the pharmaceutical sector focused on metabolism. The growing number of scientists in this field reflects the high relevance of treating diseases such as diabetes and obesity and the intensity of drug discovery.
Number of employees in the market as a whole
Structure Therapeutics is a biotech company developing small-molecule drugs for the treatment of metabolic diseases. Their growth is driven by scientific advances and clinical trial results. This employment chart does not reflect actual employment. Hiring at Structure Therapeutics is driven by drug development milestones, not economic cycles.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Structure Therapeutics (GPCR)
Structure Therapeutics is a biotech company using computational methods for drug discovery. Its value lies in its platform and intellectual property. This chart shows how investors view its innovative approach. A small team of scientists and engineers can create a pipeline of drugs with enormous potential.
%20of%20the%20company%20Structure%20Therapeutics%20(GPCR)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Structure-Therapeutics-GPCR&v=1772506746893 "Chart of market capitalization per employee (in thousands of dollars) of the company Structure Therapeutics (GPCR)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma metabolism
Structure Therapeutics (GPCR) is a biotech company using its platform to develop small-molecule drugs targeting GPCR receptors (e.g., for the treatment of obesity). Their value lies in their R&D platform. This indicator reflects the high market valuation of their scientific potential per team.
%20by%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-metabolism&v=1772506746898 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma metabolism")
Market capitalization per employee (in thousands of dollars) for the overall market
Structure Therapeutics is a biotech company developing small-molecule drugs for the treatment of metabolic diseases. Its market capitalization is based on the potential of its scientific platform. This chart shows a very high valuation per employee, typical for biotech, where a small team of scientists can discover a blockbuster drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772506746901 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Structure Therapeutics (GPCR)
Structure Therapeutics is a biotech company developing small-molecule drugs (tablets) for the treatment of metabolic diseases, including obesity (GLP-1 analogs). This is the hottest and most competitive area in pharma. This chart shows the R&D costs (negative profit) per scientist in this expensive race.
%20Chart%20Structure%20Therapeutics%20(GPCR)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Structure-Therapeutics-GPCR&v=1772506746904 "Company Profit Per Employee (in thousands of dollars) Chart Structure Therapeutics (GPCR)")
Profit per employee (in thousands of dollars) in the market segment - Pharma metabolism
Structure Therapeutics is a clinical-stage biotech company developing an oral (pill-based) GLP-1 (an anti-obesity drug). This chart shows the benchmark for the Biotech sector. In this industry, the average profit per employee is typically deeply negative. The benchmark is determined by the R&D budget being burned in the race for an anti-obesity drug.
%20in%20the%20market%20segment%20-%20Pharma%20metabolism&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-metabolism&v=1772506746907 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma metabolism")
Profit per employee (in thousands of dollars) for the market as a whole
Structure Therapeutics uses AI and computational biology to develop small-molecule drugs (pills) for the treatment of chronic diseases, such as metabolic ones. It's a biotech-IT convergence. This graph shows how the model, where AI accelerates R&D and a small team of scientists operates, compares in terms of per-employee efficiency to the market average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772506746910 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Structure Therapeutics (GPCR)
Structure Therapeutics is a biotech company using structural biology to develop drugs for metabolic diseases. While in the clinical phase, its revenue per employee is minimal or nonexistent. The chart reflects this stage, where value is created through R&D, and future revenue depends on successful trials and partnerships.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Structure-Therapeutics-GPCR&v=1772506746913 "Sales chart per company employee Structure Therapeutics (GPCR)")
Sales per employee in the market segment - Pharma metabolism
Structure Therapeutics is a clinical-stage biotech company developing oral (tablet-based) drugs for the treatment of metabolic diseases such as type 2 diabetes. This graph reflects the R&D stage. The productivity of their research team lies in creating future value through successful clinical trials, not in current sales.
Sales per employee for the market as a whole
Structure Therapeutics (GPCR) is a biotech company using its platform to develop novel oral (tablet-form) drugs targeting GPCR receptors for the treatment of metabolic diseases (e.g., obesity). This graph is typical for a clinical-stage biotech. Revenue (if any) comes from partnerships, not sales. This metric reflects the investment phase for future blockbusters.
Short shares by company, segment and market as a whole
Shares shorted by company Structure Therapeutics (GPCR)
Structure Therapeutics develops small-molecule (tablet) drugs for the treatment of metabolic diseases, primarily obesity and diabetes. They aim to compete with injectable GLP-1 (like Ozempic). This chart shows the level of skepticism. "Bears" are betting that the company will be unable to prove the efficacy or safety of its tablets compared to already approved injections from giants Novo Nordisk and Eli Lilly.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Structure-Therapeutics-GPCR&v=1772506746926 "Short Shares Chart for the Company Structure Therapeutics (GPCR)")
Shares shorted by market segment - Pharma metabolism
Structure Therapeutics (GPCR) is a biopharmaceutical company developing oral (tablet-based) drugs for the treatment of metabolic diseases, including obesity. They operate in the hyped-up GLP-1 agonist market. This chart shows bets against the pharmaceutical sector. "Shorts" here may indicate that investors are skeptical of the success of their developments amid fierce competition from giants like Novo Nordisk and Eli Lilly.
Shares shorted by the overall market
Structure (GPCR) is a clinical-stage biotech (obesity). This indicator (`Short_All`) is a mirror of market fear. When it rises, investors panic and dump risk, especially unprofitable biotechs. This pessimism, visible on the chart, deprives GPCR of access to the capital needed for expensive trials.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Structure Therapeutics (GPCR)
Structure Therapeutics is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data, but it's also at risk of a correction due to the sector's high volatility. Oversold territory (<30) often reflects research setbacks or general investor risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Structure-Therapeutics-GPCR&v=1772506746939 "RSI 14 indicator chart for the company's stock Structure Therapeutics (GPCR)")
RSI 14 Market Segment - Pharma metabolism
Structure Therapeutics is a biopharmaceutical company developing oral small molecule drugs for the treatment of metabolic diseases, including obesity (GLP-1 segment). This chart shows the overall "temperature" in the hot biotech obesity sector. It helps us understand whether the GPCR trend is driven by its own data or is simply a general "hype" sweeping the industry.
RSI 14 for the overall market
Structure Therapeutics (GPCR) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GPCR (Structure Therapeutics)
Structure Therapeutics is a biopharmaceutical company developing oral (tablet-based) drugs for the treatment of obesity and metabolic disorders, targeting the hyped GLP-1 receptor. This chart shows the average target price. Analysts' forecasts are based on clinical data and the potential of their tablets to compete with injectables.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GPCR-Structure-Therapeutics&v=1772506746960 "A chart showing analyst consensus forecasts for the expected stock price. GPCR (Structure Therapeutics)")
The difference between the consensus estimate and the actual stock price GPCR (Structure Therapeutics)
Structure Therapeutics (GPCR) is a biotech company developing oral (tablet-based) drugs for the treatment of metabolic diseases, including obesity (competitors of Ozempic). This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the high potential analysts see in their obesity pill.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GPCR-Structure-Therapeutics&v=1772506746964 "A chart showing the difference between the consensus forecast and the actual stock price. GPCR (Structure Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma metabolism
Structure Therapeutics is a biotech company developing oral (tablet) treatments for obesity and diabetes that compete with the injections of the giants. This chart shows general expectations for the metabolism sector. It reflects whether experts believe in the success of oral GLP-1 drugs.
Analysts' consensus forecast for the overall market share price
Structure Therapeutics (GPCR) is a biotech company riding the GLP-1 (obesity drug) wave. They're trying to create a pill (not a shot). This chart, reflecting expert expectations, is their risk appetite. When the market is pessimistic, investors flee cash-burning R&D projects, even trendy ones.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Structure Therapeutics
Structure Therapeutics is a biotech company using AI to create oral (pill form) versions of popular injectable drugs, primarily GLP-1 (for obesity). This chart is a pure indicator of biotech expectations. It likely aggregates their clinical trial data and market confidence in their chances of cracking the multi-billion dollar GLP-1 market.
AKIMA Market Segment Index - Pharma metabolism
Structure (GPCR) is a clinical-stage biotech focused on metabolic diseases; the company (like Viking) is developing its candidate (oral GLP-1) for the treatment of obesity. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this highly competitive (GLP-1) R&D position (GPCR) differentiate it from the average pharma company?
The AKIM Index for the overall market
Structure Therapeutics is a biotech company developing oral small molecules for the treatment of metabolic diseases (obesity, diabetes). It competes with injectables. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this hot scientific story fits in with overall economic trends and the hype surrounding GLP-1.
